ARTICLE | Company News
Halozyme, ViroPharma deal
May 16, 2011 7:00 AM UTC
Halozyme granted ViroPharma exclusive, worldwide rights to use its Enhanze recombinant human hyaluronidase ( rHuPH20) drug delivery technology to develop a subcutaneous formulation of hereditary angio...